Inclusion Criteria:  Have signed the informed consent form; Participants of both genders aged ≥ 18 years; Present acute musculoskeletal pain as a result of: ankle sprains, upper limb contusions, thigh muscle sprains, or torticollis; Present pain of moderate intensity by VAS scale (3 ≤ VAS ≤ 7); Pain onset time is less than 36 hours; Present intact skin at the trauma site; Participants of both sexes with the potential to become pregnant must be truly abstinent or use a highly effective method of contraception throughout the period of 30 days before the administration of the drug until 30 days after the end of treatment; Agree to safety laboratory tests: pregnancy test, complete blood count, and biochemical profile; Be able to understand the nature and purpose of the trial, including the risks and adverse events.  Exclusion Criteria:  Participants under the age of 18; Participants with musculoskeletal pain as a result of fractures or dislocations; Participants with mild pain (VAS < 3) at the time of selection; Participants with severe pain (VAS > 7) at the time of selection; Participants with pain onset time greater than 36 hours; Participants with a history of chronic pain and acute pain spikes; Participants with loss of skin integrity at the trauma site; Have a known hypersensitivity reaction to the trial medication or chemically related compounds; Have a prior history of the following comorbidities: asthma or other allergic conditions, uncontrolled heart failure, chronic kidney disease, chronic liver disease, active peptic ulcer disease, or gastrointestinal bleeding; Suspect for COVID-19 according to the criteria defined by the World Health Organization; Regular use of analgesics, non-steroidal analgesics or anticoagulants; Use of oral or topical corticoids in the injured area; Being on medications that have relevant interactions with the trial drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), warfarin, lithium, methotrexate, acetylsalicylic acid, corticosteroids, oral hypoglycemic agents, beta blockers, angiotensin-converting enzyme inhibitors, antihypertensive agents, and diuretics such as furosemide or thiazide; Have had oral or topical analgesic treatment, including use of non-steroidal analgesics, within 72 hours prior to the screening visit; Participants using traditional Chinese or Japanese therapy (acupuncture); Abusive use of alcoholic beverages; Women who are pregnant, breastfeeding, planning to become pregnant, or who test positive for pregnancy during the trial period; Have participated in a clinical trial within the last 12 months; Have any condition that would preclude participation in the trial in the physician's judgment.